Discovery of Isonicotinamides as Highly Selective, Brain Penetrable, and Orally Active Glycogen Synthase Kinase-3 Inhibitors.Luo, G., Chen, L., Burton, C.R., Xiao, H., Sivaprakasam, P., Krause, C.M., Cao, Y., Liu, N., Lippy, J., Clarke, W.J., Snow, K., Raybon, J., Arora, V., Pokross, M., Kish, K., Lewis, H.A., Langley, D.R., Macor, J.E., Dubowchik, G.M.
(2016) J Med Chem 59: 1041-1051
- PubMed: 26751161
- DOI: https://doi.org/10.1021/acs.jmedchem.5b01550
- Primary Citation of Related Structures:
- PubMed Abstract:
GSK-3 is a serine/threonine kinase that has numerous substrates. Many of these proteins are involved in the regulation of diverse cellular functions, including metabolism, differentiation, proliferation, and apoptosis. Inhibition of GSK-3 may be useful in treating a number of diseases including Alzheimer's disease (AD), type II diabetes, mood disorders, and some cancers, but the approach poses significant challenges. Here, we present a class of isonicotinamides that are potent, highly kinase-selective GSK-3 inhibitors, the members of which demonstrated oral activity in a triple-transgenic mouse model of AD. The remarkably high kinase selectivity and straightforward synthesis of these compounds bode well for their further exploration as tool compounds and therapeutics.
Bristol-Myers Squibb Research & Development, Bristol-Myers Squibb Company , 5 Research Parkway, Wallingford, Connecticut 06492, United States.